Literature DB >> 6853585

Simultaneous occurrence of receptors for estradiol, progesterone, and dihydrotestosterone in canine mammary tumors.

H Elling, F R Ungemach.   

Abstract

Fifty-nine canine mammary tumors have been simultaneously assayed for their histological nature and their content of cytosolic receptors for estradiol (ER), progesterone (PGR), and dihydrotestosterone (DHTR). The tumors were histologically defined as benign tumors, malignant mixed tumors, sarcomas, and simple or complex carcinomas. The tumors exhibited a high incidence of steroid receptors (ER in 61% of the tumors, PGR in 69%, DHTR in 36%). It could be demonstrated that, in cytosols of canine mammary tumors, binding sites for different steroids may simultaneously occur. Twenty four percent of the tumors were able to bind specifically all three hormones tested. No tumor class displayed a specific receptor profile in regard to the receptor incidence, KD, and binding capacity. Also no correlation could be detected between histological grading of carcinomas and receptor incidence. In these tumors, however, the amount of ER and PGR binding showed changes dependent on differentiation. Noteworthy tumors simultaneously removed from the same bitch and with identical histological diagnosis were different in their receptor characteristics.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6853585     DOI: 10.1007/bf00395750

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  28 in total

1.  Factors influencing the estimation of oestrogen receptors in human malignant breast tumours.

Authors:  H Braunsberg
Journal:  Eur J Cancer       Date:  1975-07       Impact factor: 9.162

2.  Comparison of age, sex, and incidence rates in human and canine breast cancer.

Authors:  R Schneider
Journal:  Cancer       Date:  1970-08       Impact factor: 6.860

3.  Comparative binding affinity of estrogens and its relation to estrogenic potency.

Authors:  S G Korenman
Journal:  Steroids       Date:  1969-02       Impact factor: 2.668

4.  Oestrogen receptor activity and intranuclear translocation in ovarian-dependent and -independent rat mammary tumours [proceedings].

Authors:  R A Hawkins; K M Scott; B Freedman
Journal:  J Endocrinol       Date:  1978-05       Impact factor: 4.286

Review 5.  Endocrinology in cancer of the breast. Status and prospects.

Authors:  M J Brennan
Journal:  Am J Clin Pathol       Date:  1975-12       Impact factor: 2.493

6.  Tissue-steroid interactions in canine hormone-dependent tumours.

Authors:  C R Evans; C G Pierrepoint
Journal:  Vet Rec       Date:  1975-12-13       Impact factor: 2.695

Review 7.  Current status of estrogen and progesterone receptors in breast cancer.

Authors:  W L McGuire; K B Horwitz; O H Pearson; A Segaloff
Journal:  Cancer       Date:  1977-06       Impact factor: 6.860

8.  Prognostic value of estrogen receptor determinations in patients with breast cancer.

Authors:  M A Rich; P Furmanski; S C Brooks
Journal:  Cancer Res       Date:  1978-11       Impact factor: 12.701

9.  Estrogen and progestin binding in cytosols of ovarian adenocarcinomas.

Authors:  J A Holt; T A Caputo; K M Kelly; P Greenwald; S Chorost
Journal:  Obstet Gynecol       Date:  1979-01       Impact factor: 7.661

10.  Association between steroid hormone receptors and response rate to cytotoxic chemotherapy in metastatic breast cancer.

Authors:  J C Allegra; M E Lippman; E B Thompson; R Simon; A Barlock; L Green; K K Huff; H M Do; S C Aitken; R Warren
Journal:  Cancer Treat Rep       Date:  1978-09
View more
  2 in total

1.  Changes in oestrogen, progesterone and epidermal growth factor receptor concentrations and affinities during the oestrous cycle in the normal mammary gland and uterus of dogs.

Authors:  I Donnay; P Wouters-Ballman; N Devleeschouwer; G Leclercq; J Verstegen
Journal:  Vet Res Commun       Date:  1995       Impact factor: 2.459

2.  Oestrogen (ER) and progestin receptors (PR) in mammary tissue of the female dog: different receptor profile in non-malignant and malignant states.

Authors:  G R Rutteman; W Misdorp; M A Blankenstein; W E van den Brom
Journal:  Br J Cancer       Date:  1988-11       Impact factor: 7.640

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.